Phosphodiesterase 3 inhibitors boost bone outgrowth
Several PDE3 inhibitors have been used for clinical treatment of thrombosis, heart failure and asthma, while our observations suggest that the repositioning of PDE3 inhibitors would provide novel medications for skeletal diseases characterized by short stature.
Authors
- Atsuhiko Ichimura (ORCID: https://orcid.org/0000-0003-0366-5211)
- Yohei Ueda (ORCID: https://orcid.org/0000-0003-2197-2784)
- Miyuki Nishi (ORCID: https://orcid.org/0000-0001-6055-7845)
- Naoto Minamino (ORCID: https://orcid.org/0000-0002-9913-1144)
- Hiroshi Takeshima (ORCID: https://orcid.org/0000-0003-4525-3725)
- Hiroki Nagatomo
- Takaaki Kawabe
- Tomoki Yasue
- Jianhong Li (ORCID: https://orcid.org/0009-0005-0373-0740)
- Haruki Ishikawa (ORCID: https://orcid.org/0000-0003-1499-9436)
- Hiromu Ito (ORCID: https://orcid.org/0000-0002-7143-0361)
- Ga Eun Kim
Institutions
- Ritsumeikan University (JP)
- Kyoto University (JP)
- Kyoto Pharmaceutical University (JP)
- Kurashiki Central Hospital (JP)
- National Cerebral and Cardiovascular Center (JP)
- Protein Research Foundation (JP)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-06-02
- DOI
- https://doi.org/10.1111/bph.70087
- Citations
- 1
- Primary Topic
- Phosphodiesterase function and regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Japan Foundation for Applied Enzymology
- Nakatomi Foundation
- National Cerebral and Cardiovascular Center
- Ministry of Education, Culture, Sports, Science and Technology
- Mother and Child Health Foundation
- Takeda Medical Research Foundation
- Kobayashi International Scholarship Foundation
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency